Literature DB >> 17397803

FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.

Ying Wang1, Sheng-Yu Wang, Xu-Hui Zhang, Ming Zhao, Chun-Mei Hou, Yuan-Ji Xu, Zhi-Yan Du, Xiao-Dan Yu.   

Abstract

Some pan-histone-deacetylase (HDAC) inhibitors have recently been reported to exert their anti-leukemia effect by inhibiting the activity of class IIB HDAC6, which is the deacetylase of Hsp90 and alpha-tubulin, thereby leading to hyperacetylation of Hsp90, disruption of its chaperone function and apoptosis. In this study, we compared the effect of a class I HDAC inhibitor FK228 with the pan-HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) on the Hsp90 chaperone function of K562 cells. We demonstrated that, although having a weaker inhibitory effect on HDAC6, FK228 mediated a similar disruption of Hsp90 chaperone function compared to SAHA. Unlike SAHA, FK228 did not mediate hyperacetylation of Hsp90, instead the acetylation of Hsp70 was increased and Bcr-Abl was increasingly associated with Hsp70 rather than Hsp90, forming an unstable complex that promotes Bcr-Abl degradation. These results indicated that FK228 may disrupt the function of Hsp90 indirectly through acetylation of Hsp70 and inhibition of its function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17397803     DOI: 10.1016/j.bbrc.2007.03.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Authors:  Tzu-Yin Lin; Joelle Fenger; Sridhar Murahari; Misty D Bear; Samuel K Kulp; Dasheng Wang; Ching-Shih Chen; William C Kisseberth; Cheryl A London
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

2.  Heme-dependent activation of neuronal nitric oxide synthase by cytosol is due to an Hsp70-dependent, thioredoxin-mediated thiol-disulfide interchange in the heme/substrate binding cleft.

Authors:  Yoshihiro Morishima; Miranda Lau; Hwei-Ming Peng; Yoshinari Miyata; Jason E Gestwicki; William B Pratt; Yoichi Osawa
Journal:  Biochemistry       Date:  2011-07-21       Impact factor: 3.162

Review 3.  Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions.

Authors:  David F Smith; David O Toft
Journal:  Mol Endocrinol       Date:  2008-05-01

4.  Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.

Authors:  Nadejda Beliakova-Bethell; Amey Mukim; Cory H White; Savitha Deshmukh; Hosiana Abewe; Douglas D Richman; Celsa A Spina
Journal:  J Biol Chem       Date:  2019-02-11       Impact factor: 5.157

5.  The fasted/fed mouse metabolic acetylome: N6-acetylation differences suggest acetylation coordinates organ-specific fuel switching.

Authors:  Li Yang; Bhavapriya Vaitheesvaran; Kirsten Hartil; Alan J Robinson; Michael R Hoopmann; Jimmy K Eng; Irwin J Kurland; James E Bruce
Journal:  J Proteome Res       Date:  2011-08-16       Impact factor: 4.466

Review 6.  Regulation of molecular chaperones through post-translational modifications: decrypting the chaperone code.

Authors:  Philippe Cloutier; Benoit Coulombe
Journal:  Biochim Biophys Acta       Date:  2013-02-28

Review 7.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

8.  Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.

Authors:  Chunzhang Yang; Shervin Rahimpour; Jie Lu; Karel Pacak; Barbara Ikejiri; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-31       Impact factor: 11.205

Review 9.  The tale of protein lysine acetylation in the cytoplasm.

Authors:  Karin Sadoul; Jin Wang; Boubou Diagouraga; Saadi Khochbin
Journal:  J Biomed Biotechnol       Date:  2010-11-28

Review 10.  Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Authors:  Gary E L Brandt; Brian S J Blagg
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.